RESULTS OF DIFFERENT STRATEGIES FOR REDUCING CYTOMEGALOVIRUS-ASSOCIATED MORTALITY IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS1
- 1 November 1998
- journal article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 66 (10) , 1330-1334
- https://doi.org/10.1097/00007890-199811270-00012
Abstract
Several preventive strategies against cytomegalovirus (CMV) disease have been developed during the last decade. These have frequently been used in combination, and it has been difficult to identify each strategy's contribution. Risk factors for CMV disease, death in CMV disease and transplant-related mortality were analyzed in 584 patients, who underwent a total of 594 allogeneic bone marrow transplants. The overall probability of CMV disease was 8.9%. No seronegative patient who had a seronegative marrow donor developed CMV disease. The corresponding probabilities for seronegative patients with seropositive donors, seropositive patients with seronegative donors, and seropositive patients with seropositive donors were 5.4%, 13.7%, and 11.7%, respectively. In multivariate Cox models, the use of preemptive antiviral therapy and being CMV-seronegative reduced the risk for CMV disease, CMV-associated death, and transplant-related mortality (TRM). Patients who received unrelated or mismatched family donor transplants had increased risks for CMV disease, CMV-associated death, and TRM. Older age was a significant risk factor for CMV disease and TRM. A total of 258 patients who were monitored by polymerase chain reaction for CMV DNA were analyzed separately to assess whether addition of another CMV preventive strategy could give benefit. Patients who received mismatched or unrelated donor transplants had increased risk for CMV disease, death in CMV disease, and TRM. High-dose acyclovir prophylaxis or addition of intravenous immune globulin had no influence. Preemptive therapy based on polymerase chain reaction for CMV DNA was associated with reduced risks for CMV disease, CMV-associated death, and TRM, whereas other prophylactic modalities did not give additional benefit.Keywords
This publication has 25 references indexed in Scilit:
- No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipientsBone Marrow Transplantation, 1997
- Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantationBlood, 1995
- CMV PCR monitoring in leucocytes of transplant patientsClinical and Diagnostic Virology, 1995
- A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation GroupBlood, 1994
- Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantationThe Lancet, 1994
- Ganciclovir Prophylaxis of Cytomegalovirus Infection and Disease in Allogeneic Bone Marrow Transplant Recipients: Results of a Placebo-Controlled, Double-Blind TrialAnnals of Internal Medicine, 1993
- Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow TransplantAnnals of Internal Medicine, 1993
- Detection of CMV‐matrix pp65 antigen in leucocytes by immunofluoreseence as a marker of CMV diseaseJournal of Medical Virology, 1993
- Early Treatment with Ganciclovir to Prevent Cytomegalovirus Disease after Allogeneic Bone Marrow TransplantationNew England Journal of Medicine, 1991
- Bone-Marrow TransplantationNew England Journal of Medicine, 1975